Posted by Michael Wonder on 30 Sep 2020
Saxenda is not included in the high-cost protection
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, is not included in the high-cost protection.
Novo Nordisk has applied for a subsidy for liraglutide with a restriction to patients with body mass index (BMI) over 35 (obese) and at least two weight-related complications and who have tried orlistat or when the use of orlistat is not appropriate.
TLV believes there is uncertainty about how long it will take before a patient returns to his/her initial weight after stopping treatment with liraglutide. This greatly affects the outcome of the economic evaluation.
